Semaglutide Improves Fatty Liver Disease in Diabetes Patients Over One Year
Once-weekly semaglutide improved fatty liver disease in 70% of type 2 diabetes patients over 52 weeks, with preferential loss of visceral fat over muscle mass.
Quick Facts
What This Study Found
After 52 weeks of once-weekly subcutaneous semaglutide added to metformin, 70% of type 2 diabetes patients with fatty liver disease showed improvement — reducing their liver steatosis by at least one ultrasound-assessed grade. The treatment produced significant decreases in body weight, insulin resistance, liver enzymes, and laboratory markers of hepatic fat accumulation.
Notably, semaglutide preferentially reduced fat mass and visceral adipose tissue (the dangerous belly fat surrounding organs) more than skeletal muscle or lean mass. Ultrasound-measured visceral fat thickness and a 12-point steatosis severity score both declined progressively from 3 months through the full 12-month treatment period.
Key Numbers
n=48 · 52-week treatment · 70% showed steatosis improvement by ≥1 grade · Significant decreases in VAT, liver enzymes, insulin resistance · Preferential fat loss over muscle loss
How They Did This
Forty-eight type 2 diabetes patients with NAFLD received once-weekly subcutaneous semaglutide alongside their existing metformin. They were assessed at baseline, 3 months, 6 months, and 12 months. At each visit, body composition was measured using bio-impedance analysis, and liver fat was evaluated by ultrasound imaging with a semiquantitative 12-point steatosis scoring system. Blood tests tracked glucose control, liver enzymes, insulin resistance markers, and calculated indices of hepatic steatosis.
Why This Research Matters
Nonalcoholic fatty liver disease affects roughly 70% of type 2 diabetes patients and can progress to cirrhosis and liver cancer. Until recently, there were no approved drugs specifically for NAFLD — weight loss was the only reliable treatment. This real-world study shows that semaglutide addresses both diabetes and fatty liver simultaneously, with measurable liver improvements in the majority of patients over one year. It adds to growing evidence that GLP-1 agonists may become a cornerstone treatment for metabolic liver disease.
The Bigger Picture
NAFLD is rapidly becoming one of the leading causes of liver transplants worldwide, driven by the obesity and diabetes epidemics. While several drugs are being developed specifically for fatty liver disease, GLP-1 agonists like semaglutide are emerging as a treatment that hits multiple metabolic targets at once — blood sugar, body weight, visceral fat, and liver health. Real-world studies like this one complement the larger clinical trials and show that these benefits translate to everyday clinical practice.
What This Study Doesn't Tell Us
This was a single-center, uncontrolled prospective study with only 48 patients — there was no placebo or comparison group, so improvements can't be definitively attributed to semaglutide alone versus lifestyle changes or natural progression. The use of ultrasound rather than MRI for liver fat assessment is less precise. As a real-world study, treatment adherence and concurrent lifestyle modifications weren't strictly controlled.
Questions This Raises
- ?Would semaglutide's liver benefits persist if the drug were stopped, or would fatty liver return with weight regain?
- ?How does semaglutide compare to dedicated NAFLD treatments like resmetirom (the first FDA-approved drug for metabolic liver disease)?
- ?Could higher doses of semaglutide produce even greater liver improvements, or is there a ceiling effect?
Trust & Context
- Key Stat:
- 70% improved Seven in ten type 2 diabetes patients saw their fatty liver disease improve by at least one severity grade after 52 weeks of semaglutide
- Evidence Grade:
- This is a prospective real-world study with consistent follow-up over 12 months and multiple objective outcome measures. However, the lack of a control group, small sample size (n=48), and single-center design limit the strength of causal conclusions.
- Study Age:
- Published in 2022, this study is recent and relevant. It aligns with growing evidence from larger trials (like the phase 2 semaglutide NASH trial) supporting GLP-1 agonists for metabolic liver disease.
- Original Title:
- Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
- Published In:
- Nutrients, 14(21) (2022)
- Authors:
- Volpe, Sara, Lisco, Giuseppe, Fanelli, Margherita, Racaniello, Davide, Colaianni, Valentina, Triggiani, Domenico, Donghia, Rossella, Crudele, Lucilla, Rinaldi, Roberta, Sabbà, Carlo, Triggiani, Vincenzo, De Pergola, Giovanni, Piazzolla, Giuseppina
- Database ID:
- RPEP-06569
Evidence Hierarchy
Enrolls participants and follows them forward in time.
What do these levels mean? →Frequently Asked Questions
Can semaglutide treat fatty liver disease, not just diabetes?
This study suggests yes. After one year of once-weekly semaglutide, 70% of patients with both type 2 diabetes and fatty liver disease showed measurable improvement in liver fat on ultrasound. The drug reduced visceral fat, liver enzymes, and insulin resistance — all key drivers of NAFLD. While semaglutide isn't specifically approved for fatty liver, these results add to evidence that it treats metabolic liver disease alongside diabetes.
Does semaglutide cause muscle loss along with fat loss?
A concern with any weight loss treatment is losing muscle along with fat. In this study, semaglutide preferentially reduced fat mass and visceral adipose tissue (dangerous belly fat) more than skeletal muscle and lean mass. While some lean mass reduction is expected with any weight loss, the favorable ratio seen here is reassuring for long-term metabolic and physical health.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06569APA
Volpe, Sara; Lisco, Giuseppe; Fanelli, Margherita; Racaniello, Davide; Colaianni, Valentina; Triggiani, Domenico; Donghia, Rossella; Crudele, Lucilla; Rinaldi, Roberta; Sabbà, Carlo; Triggiani, Vincenzo; De Pergola, Giovanni; Piazzolla, Giuseppina. (2022). Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.. Nutrients, 14(21). https://doi.org/10.3390/nu14214673
MLA
Volpe, Sara, et al. "Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.." Nutrients, 2022. https://doi.org/10.3390/nu14214673
RethinkPeptides
RethinkPeptides Research Database. "Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Di..." RPEP-06569. Retrieved from https://rethinkpeptides.com/research/volpe-2022-onceweekly-subcutaneous-semaglutide-improves
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.